<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="135892">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01332396</url>
  </required_header>
  <id_info>
    <org_study_id>113092</org_study_id>
    <nct_id>NCT01332396</nct_id>
  </id_info>
  <brief_title>Drug Use Investigation for TYKERB Tablet (All Case Investigation)</brief_title>
  <official_title>Drug Use Investigation for TYKERB Tablet (All Case Investigation)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Data on the safety and efficacy of TYKERB shall be collected from the patients in order to
      grasp the actual conditions of post-marketing use and assess background information on the
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>The incidence of adverse events in Japanese patients treated with TYKERB based on prescribing information under the conditions of general clinical practice</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Patients prescribed TYKERB</arm_group_label>
    <description>Patients with HER2 overexpressing inoperable or recurrent breast cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lapatinib</intervention_name>
    <arm_group_label>Patients prescribed TYKERB</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients who have &quot;HER2 overexpressing inoperable or recurrent breast cancer&quot; and have
        received TYKERB for the first time
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with HER2 overexpressing inoperable or recurrent breast cancer

        Exclusion Criteria:

          -  Patients with hypersensitivity to lapatinib or any components

          -  Pregnant women and women suspected of being pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 17, 2016</lastchanged_date>
  <firstreceived_date>April 7, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lapatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
